Stocks
Madrigal Pharmaceuticals, Inc.MDGL
NASDAQHealthcareBiotechnology$444.83+1.39%
Focused on developing therapies for nonalcoholic steatohepatitis (NASH) and other liver diseases, this biopharmaceutical company has gained investor attention for its lead candidate, resmetirom, which targets a significant unmet medical need. Madrigal Pharmaceuticals is positioned as a key player in the NASH treatment market, with its clinical-stage assets closely watched for their commercial potential.
Market Cap: $10.1B52W Range: $265.00 – $615.00
Congressional Interest in Madrigal Pharmaceuticals, Inc. (MDGL)
1 member of Congress has disclosed 1 trade in Madrigal Pharmaceuticals, Inc. (MDGL), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading MDGL?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |